NEW YORK AP - Mylan Inc. said Wednesday it can launch an authorized generic version of Pfizer Inc.'s antifungal drug Vfend in early 2011 under terms of a patent lawsuit settlement between the drugmakers.Mylan said it will be able to market generic Vfend tablets in the U.S. starting in the first quarter of 2011, and said it may have 180 days of marketing exclusivity for its product.
October 14, 2009 at 12:00 AM
1 minute read
NEW YORK AP – Mylan Inc. said Wednesday it can launch an authorized generic version of Pfizer Inc.’s antifungal drug Vfend in early 2011 under terms of a patent lawsuit settlement between the drugmakers.
Mylan said it will be able to market generic Vfend tablets in the U.S. starting in the first quarter of 2011, and said it may have 180 days of marketing exclusivity for its product. The agreement covers 50 milligram and 200 milligram tablets of the drug, which is also called voriconazole.
Presented by BigVoodoo
This event shines a spotlight on the individuals, teams, projects and organizations that are changing the financial industry.
BTI provides leading tax professionals from financial institutions with unmatched tools and resources.
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
CORE RESPONSIBILITIES AND TASKS:(1) Tasks and responsibilities include:Reviewing and negotiating commercial agreements for internal business...
Boutique midtown Manhattan law firm specializing in sophisticated real estate litigation & representation of commercial and residential ...
Description: Fox Rothschild has an opening in the Boston, MA office for a Litigation Associate with 3 to 5 years of experience. The ideal ca...
